Level 2

Company Announcements

Issue of Equity

Related Companies

By LSE RNS

RNS Number : 0061X
Clinigen Group plc
20 November 2017
 

20 November 2017

 

Issue of Equity

Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 45,948 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These ordinary shares have been issued to satisfy share options vesting under The Clinigen Group All Staff Long Term Incentive Plan and The Clinigen Group All Staff JV Long Term Incentive Plan and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 23 November 2017.

 

At admission the issued share capital of the Group will consist of 122,268,158 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 122,268,158. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.

 

-Ends-

 

Contact details

 

Clinigen Group plc

Tel: +44 (0) 1283 495010

Shaun Chilton, Group Chief Executive Officer


Martin Abell, Group Chief Financial Officer




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Tom Ballard  (Corporate Broking)




RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas / Jack Wood




Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Alex Shaw / Deborah Bell

Email: clinigen@instinctif.com

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.

 

For more information, please visit www.clinigengroup.com 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEFEDFLSFWSELF

Top of Page